Hines is one of relatively few enrollees to have used the new Medicaid benefit, which weight loss doctors in the state say has been hindered by national drug shortages, the states prior authorization process for the drugs, and a lack of marketing
[DOI] [PMC free article] [PubMed] [Google Scholar] 26.Martinot E, Sdes L, Baptissart M, et al
39 Although GLP-1RAs continue to be promising therapies for T2D, their long-term efficacy for weight loss after halting treatment should be further improved
The safest conclusion is simple: treat patch claims as unverified until proven, because most consumer patches do not provide enough reliable data to confirm a medication level mechanism, and large peptides do not cross intact skin the way the ads imply
For instance, semaglutide has been approved and is being researched for indications including obesity, T2DM, reducing cardiovascular risk, chronic kidney disease, NAFLD, and AD, indicating that the development of new indications could provide new growth opportunities for GLP-1 drugs
